Results 151 to 160 of about 70,073 (274)

Immunotherapy in metastatic castration-resistant prostate cancer: transformative for the few, not for all. [PDF]

Transl Androl Urol
de Souza VPB, Barata PC.
europepmc   +1 more source

Sex Matters: Hormonal and Chromosomal Determinants of Autoimmunity and Anti‐Cancer Immunity Across the Lifespan

Immunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT Sex plays a key role in shaping both anti‐cancer immunity and autoimmunity. Biological factors underlying sexual dimorphism have now been identified in multiple aspects of anti‐cancer immunity and autoimmunity. These factors include sex differences in hormone levels, chromosome complement, and expression of the long non‐coding RNA XIST.
Christian G. Bustillos, Esther M. Peluso, Sophia L. Cha, Melissa G. Lechner, Maureen A. Su   +4 more
wiley   +1 more source

Bipolar androgen therapy as platform for personalized medicine in castration-resistant prostate cancer. [PDF]

Discov Oncol
Lilleby W, Geinitz H, Denmeade S.
europepmc   +1 more source

Sex Differences in Cancer Immunotherapy—Clinical Evidence and Mechanisms With a Focus on NSCLC

Immunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT Accumulating evidence suggests that the immune system shows subtle but relevant differences between men and women. These differences may have an impact on cancer development and TME composition as well as responses to and adverse events elicited by immunotherapies.
Eva Krieghoff‐Henning, Balagopal Pai, Maike Collienne, Isabel Ben‐Batalla, Sonja Loges   +4 more
wiley   +1 more source

The Histone Methyltransferase KMT2D Is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration-Resistant Prostate Cancer. [PDF]

Cancer Res
Kittane S, Ladewig E, Li T, Love JR, Blawski R, Gao Y, Arruabarrena-Aristorena A, Zhao P, Dalrymple SL, Liu H, Guo X, Sallaku M, Kelkar N, Garcia-Martinez L, Carmona Sanz J, Chen W, Stoudmann C, Baldino L, Razavi-Mohseni M, Kalemi I, Beer MA, Castel P, Brennen WN, Scaltriti M, Morey L, Cocco E, Ji H, Chan HM, Battle A, Leslie CS, Karthaus WR, Toska E.   +31 more
europepmc   +1 more source

ODC1 Polyamine Metabolism Drives Prostate Cancer via AKT and Splicing

Journal of Cellular and Molecular Medicine, Volume 30, Issue 5, March 2026.
ABSTRACT Prostate cancer is an aggressive disease with limited quantifiable biomarkers. One gene of interest is ODC1, which encodes ornithine decarboxylase, the rate‐limiting enzyme converting ornithine to putrescine in polyamine metabolism. Although ODC1 is known to be involved in prostate cancer development, exactly how it drives the disease ...
Jian Ma, Ting Pan, Shengli Sun, Musitapa Mutalifu, Wei Yang, Yue Niu, Peng Chen   +6 more
wiley   +1 more source

Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer. [PDF]

JAMA Netw Open
Barata PC, Corrigan JK, La J, Culnan JM, Akama-Garren E, Dulberger KN, Dumontier C, Hansen J, Bihn JR, Bitting RL, Brophy MT, Cheng HH, Cooperberg MR, Do NV, Dorff T, Fojo AT, Gaziano JM, Goryachev SD, Halabi S, Hauger RL, Nanus DM, Rebbeck TR, Pan CX, Schoen MW, Swinnerton KN, Myrie K, Ramoni RB, Fillmore NR, Paller CJ, Rettig MB.   +29 more
europepmc   +1 more source

Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer. [PDF]

BMC Cancer
Lapointe-Belleau A, Rouleau M, Villeneuve L, Descarreaux J, Caron P, Beaudoin C, Uchil A, Simonyan D, Dahmani C, Joly-Beauparlant C, Gélinas V, Droit A, Marcoux N, Castonguay V, Lacombe L, Lévesque É, Guillemette C.   +16 more
europepmc   +1 more source

Rethinking combination strategies in metastatic castration-resistant prostate cancer (mCRPC)-lessons from KEYNOTE-641. [PDF]

Transl Androl Urol
Nguyen MD, Vinh-Hung V, Verschraegen C, Wang P.   +3 more
europepmc   +1 more source

Two Cases of Metastatic Castration-Resistant Prostate Cancer With Long-Term Survival Treated With Abiraterone. [PDF]

Clin Case Rep
Une M, Yamamoto S, Fuse H, Fujiwara R, Yonese J, Noda K.   +5 more
europepmc   +1 more source